• Tempus AI posted Q2 revenue of $382.5 million, up 22% year-over-year; GAAP net income swung to $5.6 million.
• Adjusted EBITDA turned positive at $8 million; oncology volume rose 31% year-over-year, while MRD volume climbed to 9,000 tests from 6,500 last quarter.
• Data and Applications revenue increased 28% year-over-year to $93.2 million; Data Licensing & Modeling (Insights) revenue rose 36%.
• Signed about $200 million in new Data and Applications licenses; FDA cleared the tumor-only xT CDx assay, enabling migration of tissue testing to ADLT pricing.
• Raised 2026 revenue guidance to $1.595-$1.605 billion; reiterated expected full-year adjusted EBITDA of about $65 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607301601BIZWIRE_USPR_____20260730_BW328545) on July 30, 2026, and is solely responsible for the information contained therein.